camp4 therapeutics corp. - CAMP

CAMP

Close Chg Chg %
5.33 0.45 8.44%

Closed Market

5.78

+0.45 (8.44%)

Volume: 65.12K

Last Updated:

Nov 21, 2024, 4:00 PM EDT

Company Overview: camp4 therapeutics corp. - CAMP

CAMP Key Data

Open

$6.00

Day Range

5.58 - 6.30

52 Week Range

N/A - N/A

Market Cap

$103.96M

Shares Outstanding

19.51M

Public Float

3.26M

Beta

N/A

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

N/A

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

63.41K

 

CAMP Performance

1 Week
 
-28.82%
 
1 Month
 
-48.35%
 
3 Months
 
N/A
 
1 Year
 
N/A
 
5 Years
 
N/A
 

CAMP Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About camp4 therapeutics corp. - CAMP

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP At a Glance

CAMP4 Therapeutics Corp.
One Kendall Square
Cambridge, Massachusetts 02139
Phone 1-617-651-8867 Revenue 350.00K
Industry Biotechnology Net Income -49,291,000.00
Sector Health Technology Employees 58
Fiscal Year-end 12 / 2024
View SEC Filings

CAMP Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA N/A
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

CAMP Efficiency

Revenue/Employee 6,034.483
Income Per Employee -849,844.828
Receivables Turnover 0.792
Total Asset Turnover 0.004

CAMP Liquidity

Current Ratio 5.125
Quick Ratio 5.125
Cash Ratio 4.916

CAMP Profitability

Gross Margin -421.143
Operating Margin -14,822.571
Pretax Margin -14,083.143
Net Margin -14,083.143
Return on Assets -62.594
Return on Equity -80.126
Return on Total Capital -97.413
Return on Invested Capital -69.533

CAMP Capital Structure

Total Debt to Total Equity 31.713
Total Debt to Total Capital 24.077
Total Debt to Total Assets 22.173
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 17.233
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Camp4 Therapeutics Corp. - CAMP

Collapse All in section
All values USD millions. 2022 2023 5-year trend
Sales/Revenue
- - - 350.00K
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
- - 947.00K 1.82M
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- - 947.00K 1.82M
-
Depreciation
- - 947.00K 1.82M
-
Amortization of Intangibles
- - - -
-
COGS Growth
- - - +92.61%
-
Gross Income
- - (947.00K) (1.47M)
-
Gross Income Growth
- - - -55.65%
-
Gross Profit Margin
- - - -421.14%
-
2022 2023 5-year trend
SG&A Expense
- - 44.05M 50.41M
-
Research & Development
- - 33.82M 38.79M
-
Other SG&A
- - 10.23M 11.61M
-
SGA Growth
- - - +14.42%
-
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
- - (45.00M) (51.88M)
-
Non Operating Income/Expense
- - 809.00K 2.59M
-
Non-Operating Interest Income
- - 904.00K 2.81M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
- - (44.19M) (49.29M)
-
Pretax Income Growth
- - - -11.54%
-
Pretax Margin
- - - -14,083.14%
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
- - (44.19M) (49.29M)
-
Minority Interest Expense
- - - -
-
Net Income
- - (44.19M) (49.29M)
-
Net Income Growth
- - - -11.54%
-
Net Margin Growth
- - - -14,083.14%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
- - (44.19M) (49.29M)
-
Preferred Dividends
- - - -
-
Net Income Available to Common
- - (44.19M) (49.29M)
-
EPS (Basic)
- - -2.2657 -2.5271
-
EPS (Basic) Growth
- - - -11.54%
-
Basic Shares Outstanding
- - 19.51M 19.51M
-
EPS (Diluted)
- - -2.2657 -2.5271
-
EPS (Diluted) Growth
- - - -11.54%
-
Diluted Shares Outstanding
- - 19.51M 19.51M
-
EBITDA
- - (44.05M) (50.05M)
-
EBITDA Growth
- - - -13.62%
-
EBITDA Margin
- - - -14,301.43%
-

Snapshot

Average Recommendation BUY Average Target Price 27.43
Number of Ratings 4 Current Quarters Estimate -0.739
FY Report Date 12 / 2024 Current Year's Estimate -5.52
Last Quarter’s Earnings -24.19 Median PE on CY Estimate N/A
Year Ago Earnings N/A Next Fiscal Year Estimate -2.999
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 2 4 4
Mean Estimate -0.74 -0.77 -5.52 -3.00
High Estimates -0.55 -0.65 -3.73 -2.61
Low Estimate -0.85 -0.88 -9.35 -3.50
Coefficient of Variance -17.54 -21.35 -47.39 -12.51

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4
OVERWEIGHT 0
HOLD 0
UNDERWEIGHT 0
SELL 0
MEAN Buy

Insider Actions for Camp4 Therapeutics Corp. - CAMP

Date Name Shares Transaction Value
Jun 6, 2024 Jason W. Cohenour Director N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.83 per share 0.00
May 8, 2024 Jikun Kim Chief Financial Officer 8,885 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $3.68 per share 32,696.80
Mar 8, 2024 Jason W. Cohenour Director 8,640 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.38 per share 20,563.20
Mar 8, 2024 Jason W. Cohenour Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Camp4 Therapeutics Corp. in the News